Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Investment: Sharewatch

Wednesday 24 February 1999 00:02 GMT
Comments

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

BUY

Glaxo Wellcome's story just gets better, says BT Alex.Brown, which has repeated its buy recommendation (2018p) on the pharmaceutical giant's stock. SG Securities also considers it a buy (2021p), encouraged by the performance in its respiratory and HIV portfolios, while Teather & Greenwood notes that "with one of the most productive pipelines, double-digit earnings from 1999 are achievable".

HOLD

Sutherlands has upgraded Ulster Television (220p) from reduce to hold after the Northern Ireland franchise holder reported a rise in profits on Monday, boosted by the sale of a sixth of its stake in Societe Europeenne des Satillites, and announced a 35p special dividend.

Full-year results from Halifax last week and news of pounds 1.5bn return of capital in June pleased analysts, with Teather & Greenwood upgrading the stock from sell to hold, and Merrill Lynch moving from neutral to buy for the long-term. BT Alex.Brown, held its recommendation on the shares at underperform (780p).

SELL

Merrill Lynch has downgraded property developer Slough Estates (325p) to neutral, citing a longer-term concern over its overseas developments. Slough's 44 per cent exposure to offices and industrials in the Thames Valley area should be defensive, Merrill adds.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in